ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $24.00 price objective on the stock.

Several other equities analysts also recently weighed in on IBRX. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research note on Wednesday, September 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $10.75.

ImmunityBio Trading Down 2.7%

Shares of IBRX stock traded down $0.06 during mid-day trading on Thursday, reaching $2.01. The stock had a trading volume of 5,848,568 shares, compared to its average volume of 8,314,733. The stock’s 50-day moving average price is $2.46 and its two-hundred day moving average price is $2.57. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $5.43. The firm has a market capitalization of $1.97 billion, a PE ratio of -4.89 and a beta of 0.29.

Hedge Funds Weigh In On ImmunityBio

A number of hedge funds and other institutional investors have recently made changes to their positions in IBRX. Armistice Capital LLC acquired a new stake in shares of ImmunityBio during the second quarter worth approximately $20,497,000. Vanguard Group Inc. increased its holdings in shares of ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after purchasing an additional 5,837,898 shares during the period. AlphaCore Capital LLC bought a new stake in ImmunityBio during the second quarter worth approximately $7,854,000. Citigroup Inc. boosted its stake in ImmunityBio by 605.9% during the first quarter. Citigroup Inc. now owns 2,714,662 shares of the company’s stock valued at $8,171,000 after buying an additional 2,330,086 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in ImmunityBio by 34.7% during the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after acquiring an additional 1,487,849 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.